Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study.
Data from the phase III ASCENT-04/KEYNOTE-D19 showed Trodelvy plus Merck 's MRK blockbuster immuno-oncology drug Keytruda reduced the risk of disease progression or death by 35% compared with Keytruda and chemotherapy in first-line PD-L1+ metastatic triple-negative breast cancer (TNBC).
Gilead and Merck collaborated in 2021 to evaluate Trodelvy in combination with Keytruda in the phase III ASCENT-04/KEYNOTE-D19 study.
Shares of GILD have gained 20% year to date against the industry 's decline of 3.1%.
More on GILD's & MRK's ASCENT-04/KEYNOTE-D19 Study
The ASCENT-04/KEYNOTE-D19 study is a global, open-label, randomized phase III study evaluating the efficacy and safety of Trodelvy in combination with Keytruda compared with the treatment of chemotherapy plus Keytruda in patients with previously untreated, inoperable locally advanced or metastatic TNBC whose tumors express PD-L1.
The study enrolled 443 patients across multiple study sites.
Patients were randomized equally in two arms - to receive either Trodelvy (10 mg/kg intravenously on Days one and eight of a 21-day cycle) plus Keytruda (200 mg intravenously on Day one of a 21-day cycle) or chemotherapy plus Keytruda.
The chemotherapy regimen included gemcitabine plus carboplatin, paclitaxel, or nab-paclitaxel.
Patients continued treatment until either blinded independent central review (BICR)-verified disease progression or unacceptable toxicity. Importantly, those who progress on chemotherapy can cross over to receive Trodelvy.
The primary endpoint of the study is progression-free survival (PFS) as determined by BICR using RECIST v1.1. Secondary endpoints include overall survival (OS), objective response rate (ORR), duration of response (DOR), time to onset of response (TTR), patient-reported outcomes (PROs) and safety.
In April 2025, GILD announced that the study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS.
A highly statistically significant and clinically meaningful improvement was observed with Trodelvy plus Keytruda, with a 35% reduction in the risk of disease progression or death in the intent-to-treat population compared to the standard of care Keytruda plus chemotherapy combination.
A numerically higher overall response rate was observed for the Trodelvy plus Keytruda combination. Additionally, a substantially longer DOR was observed with the combination ofTrodelvy plus Keytruda
While data showed encouraging trends in overall survival (OS), it was still immature at the time of PFS primary analysis. OS follow-up remains ongoing and will continue to be monitored as a key secondary endpoint.
The safety profile of Trodelvy plus Keytruda in the ASCENT-04 study was consistent with the known safety profile of both drugs.
GILD Looks to Expand Trodelvy's Label
TNBC is the most aggressive type of breast cancer. In particular, first-line options remain limited for patients with PD-L1–positive metastatic TNBC.
Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate.
Trodelvy is currently approved in more than 50 countries for second-line or later mTNBC patients and in several countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer.
Last month, Gilead posted positive top-line results from another late-stage study, ASCENT-03, on Trodelvy. Data from this phase III study showed highly statistically significant and clinically meaningful improvement in PFS in patients with first-line metastatic TNBC who are not candidates for checkpoint inhibitors.
This is the second positive phase III study in first-line mTNBC where Trodelvy has demonstrated a clinically meaningful benefit compared with standard of care chemotherapy.
Per GILD, positive data from the ASCENT-03 and ASCENT-04 study demonstrate Trodelvy's potential as the backbone treatment for all patients across first-line mTNBC.
Gilead has additional ongoing phase III studies evaluating Trodelvy across HER2 breast cancer, including the ASCENT-07 pivotal trial in patients with HR+/HER2- mBC who have received endocrine therapy, and the ASCENT-05 pivotal trial in patients with early-stage TNBC (eTNBC). The drug is also being evaluated in additional late-stage studies across a range of tumor types, including lung and gynecologic cancers.
Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025.
Nonetheless, the potential launch of anito-cel in multiple myeloma and Trodelvy in first-line metastatic TNBC in 2026 will strengthen the company's oncology business.
GILD's Zacks Rank and Stocks to Consider
Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer PFE, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year.
Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
English pop singer Jessie J says she has been diagnosed with early breast cancer
The English pop singer Jessie J says she has been diagnosed with breast cancer and will undergo surgery after her performance at the London music festival Capital's Summertime Ball next weekend. Jessie J, 37, shared the news in an Instagram video on Wednesday. 'I was diagnosed with early breast cancer,' she said in the clip. 'Cancer sucks in any form, but I'm holding onto the word 'early'.' 'It's a very dramatic way to get a boob job. I am going to disappear for a bit after Summertime Ball to have my surgery, and I will come back with massive (expletive) and more music.' The annual Summertime Ball will be held at Wembley Stadium on Sunday, June 15. She told her social-media audience that she felt compelled to share her diagnosis. Gen X and millennials blindsided by rising rates of cancer 'I just wanted to be open and share it,' she said. 'One, because, selfishly, I do not talk about it enough. I'm not processing it because I'm working so hard. I also know how much sharing in the past has helped me with other people giving me their love and support and also their own stories. I'm an open book. It breaks my heart that so many people are going through so much similar and worse – that's the bit that kills me.' The Grammy-nominated Jessie J has long been celebrated for her robust soprano and R&B-informed pop hits, like the 2014 collaboration with Nicki Minaj and Ariana Grande, Bang Bang, and 2011's Domino. She has released five albums across her career, most recently, 2018's Christmas album, This Christmas Day. She has been releasing new music in 2025, including the singles Living My Best Life and No Secrets. A new album is expected later this year. She has a son, Sky Safir Cornish Colman, born in 2023. A representative for Jessie J did not immediately respond to the Associated Press' request for comment.
Globe and Mail
29 minutes ago
- Globe and Mail
How Walmart's Physical Stores Are Powering Its Digital Expansion
Walmart's WMT success continues to be powered by its strong omnichannel strategy, which blends physical stores with digital shopping. The company is constantly improving how it serves customers by using data, investing in technology and making in-store operations more efficient. Because most Americans live close to a Walmart, the company can use its stores to quickly fulfill online orders. It has taken many steps to improve its e-commerce business, such as buying other companies, forming partnerships and upgrading its delivery and payment systems. In the first quarter of fiscal 2026, Walmart's global e-commerce sales grew by 22%, thanks to more customers using online shopping across all its divisions. In the United States, e-commerce sales rose 21%, driven by fast store-fulfilled pickup and delivery, strong marketplace sales and growth in advertising. More customers are choosing faster delivery options for convenience. International e-commerce sales increased 20%, also supported by store-based pickup and delivery and growing marketplace demand. At Sam's Club U.S., e-commerce sales jumped 27%, with major gains in Club-fulfilled deliveries and pickup services. Walmart is also building out its supply chain and expanding key digital businesses like Walmart GoLocal (last-mile delivery), Walmart Connect (advertising), Walmart Luminate (data insights), Walmart+ (membership program) and Walmart Fulfillment Services (helping sellers deliver products). It has made smart investments such as acquiring a large stake in Flipkart, a leading e-commerce platform in India, and owning most of PhonePe, a digital payments company. Walmart has also been growing quickly in online grocery shopping, which remains a major driver of its digital success. Key Competitors Challenging WMT in E-Commerce Amazon AMZN is the top player in online shopping, thanks to its huge product range, fast delivery and strong marketplace with many third-party sellers. Its strategy focuses on speed, convenience and keeping customers loyal through Prime, which offers free shipping and other perks. Amazon keeps investing in better technology, AI and faster fulfillment. Recently, its online sales have grown again after a slower period. However, Walmart is catching up by using its many stores to quickly deliver online orders, especially in groceries, where it has a clear advantage. The race between Amazon and Walmart is getting closer. Target's TGT e-commerce business is growing fast because of its focus on making shopping easy and quick. They offer services like same-day delivery and curbside pickup, using their stores to help fulfill online orders. This has helped Target's online sales grow a lot. In the first quarter of 2025, Target's e-commerce operations contributed approximately 20% to the company's total revenues. Target relies on its unique brand and loyal shoppers to compete with Walmart's size and low prices. WMT's Price Performance, Valuation, and Estimates Shares of Walmart have gained around 10.6% year to date compared with the industry 's growth of 10.8%. From a valuation standpoint, WMT trades at a forward price-to-earnings ratio of 37.08X, significantly above the industry's average of 33.95X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for WMT's 2025 earnings implies year-over-year growth of 3.2%, whereas its 2026 earnings estimate suggests a year-over-year uptick of 11.6%. The estimates for 2025 and 2026 have been stable in the past seven days. WMT stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Target Corporation (TGT): Free Stock Analysis Report Walmart Inc. (WMT): Free Stock Analysis Report
Globe and Mail
29 minutes ago
- Globe and Mail
Tiny Dreamers Studio Recognized as Top Photo Studio in Greater Sacramento
Sacramento, California--(Newsfile Corp. - June 4, 2025) - Tiny Dreamers Studio, a leading newborn and family photography studio, has been named one of the best photo studios in the Greater Sacramento area by This recognition highlights the studio's commitment to capturing precious moments and delivering exceptional quality to its clients. To view an enhanced version of this graphic, please visit: a respected authority in the photography industry, conducted an extensive review of photo studios in the region. Tiny Dreamers Studio stood out for its innovative techniques, attention to detail, and ability to create timeless memories for families. "We are thrilled to be recognized as one of the top photo studios in Greater Sacramento," said Tiny Dreamers Studio founder Bree Franklin. "This acknowledgment is a testament to our team's dedication and passion for capturing the most cherished moments in our clients' lives." To view an enhanced version of this graphic, please visit: The studio's specialization in newborn and family photography has earned it a loyal following among local families. Tiny Dreamers Studio is known for its safe and comfortable environment, state-of-the-art equipment, and creative approach to preserving life's milestones. This recognition comes as Tiny Dreamers Studio celebrates over 10 years of service to the Greater Sacramento community. The studio has photographed hundreds of newborns and families, creating lasting memories for countless households in the area. To view an enhanced version of this graphic, please visit: Looking ahead, Tiny Dreamers Studio plans to expand its services and continue innovating in newborn and family photography. The studio is committed to maintaining its high standards and pushing the boundaries of creativity in capturing life's precious moments. For more information about Tiny Dreamers Studio and its services, please visit or contact Bree Franklin at bree@ About Tiny Dreamers Studio: Tiny Dreamers Studio is a premier newborn and family photography studio in Greater Sacramento, California. Founded in 2010, the studio creates timeless, high-quality images that capture the essence of family bonds and the wonder of new life. Focusing on safety, creativity, and client satisfaction, Tiny Dreamers Studio has become a trusted name in preserving precious memories for families throughout the Greater Sacramento area.
